Wegovy duration of treatment: how long do you take it?

The two-year figure: where it comes from and what it actually means

A question our prescribers hear most weeks is some version of: "Am I supposed to stop after two years?" The short answer is that two years is not a hard biological clock, it is a boundary set by NICE in its appraisal of semaglutide (TA875) specifically for NHS prescribing through specialist weight management services. Under that guidance, continuing beyond 24 months requires clinical justification within a multidisciplinary programme.

Private prescribing follows the licensed indication, which does not impose a fixed upper limit. The SmPC licences Wegovy for ongoing weight management in eligible adults, full stop. So the right framing is not "when must I stop" but "is this medicine still working, is it still appropriate, and is my prescriber satisfied with ongoing use?" Those are the questions a clinical review answers, not a countdown timer.

What the two-year figure does usefully signal is that this is not a short-term medicine. The STEP 1 trial, published in the New England Journal of Medicine, ran to 68 weeks and showed an average body-weight reduction of around 15% at the 2.4mg dose. That kind of result accumulates over months, not days. Expecting meaningful change after four or six weeks misreads how the medicine works.

What the six-month review point tells your prescriber

At six months on the full maintenance dose, there is a defined checkpoint: if you have not lost at least 5% of your starting body weight, the clinical guidance (from both NICE TA875 and NHS England) is to reconsider whether continuing is appropriate. This is not a punishment clause; it reflects the honest reality that semaglutide does not produce the same response in every person, and a medicine that is not working should not continue indefinitely.

If the response is good, the six-month review becomes the first of many ongoing assessments. Weight management with a GLP-1 medicine is monitored continuously, not prescribed once and left alone. At nume, every repeat order goes through a clinical re-review, a named prescriber reads the updated information before anything is dispatched. You can read more about how that process fits into the broader picture on our about us page.

It is also worth knowing that titration takes time before that review is even meaningful. The standard titration schedule moves through several doses over roughly four months before reaching 2.4mg maintenance. Judging the medicine's effect before the maintenance dose is reached misses the point of the graduation schedule entirely.

Why stopping Wegovy tends to reverse the weight loss

This is the part of the conversation that surprises people most. Clinical trial data (including a STEP 1 extension study) found that participants who stopped semaglutide after 68 weeks regained most of the lost weight within a year. The biology is straightforward: semaglutide works partly by dampening appetite signals that the body produces continuously. When the medicine stops, those signals return to baseline. The weight that returns is not a treatment failure; it reflects the underlying condition reasserting itself.

This is precisely why the decision to stop deserves as much clinical attention as the decision to start. Some people reach a point where lifestyle changes have consolidated well enough to sustain a lower weight independently. Others find that their weight-related conditions (blood pressure, blood sugar, joint load) deteriorate quickly if treatment stops. Only a prescriber who knows your history can weigh that up. For context on how Wegovy's mechanism drives appetite suppression, our overview page covers the physiology in more detail.

Thinking about the cost of longer-term treatment is entirely reasonable. Our Wegovy pricing page sets out what is included in a single transparent price (consultation, prescription, and delivery) so you can plan without guesswork.

Practical questions for your prescriber before committing to a duration

Rather than asking "how long will I be on this", the more productive questions are: what would prompt a dose change, what would prompt a review of whether to continue, and what does stopping look like if it becomes the right decision? A prescriber who can answer those clearly is one who is genuinely managing your treatment rather than processing a repeat.

Diet matters throughout. The evidence behind Wegovy assumes an accompanying reduced-calorie diet and increased physical activity, these are not optional extras tacked onto the licence wording, they are baked into the trial design. Our guide to eating well while on Wegovy covers practical food choices that work alongside the medicine. What you eat affects not just weight loss velocity but how manageable the GI side effects are, particularly in the early titration months.

If you are exploring treatment for the first time or reconsidering an existing course, the starting point is a clinical consultation. The prescriber can map your situation (weight history, existing conditions, current medications) against what the evidence supports. That conversation is free at nume, with same-day review by a GPhC-registered prescriber.